SavedAdd your journal

Journals / Archives of Rheumatology / 2022 / Cilt: 37 - Sayı: 1

Commensalism or symbiosis: The potential use of rituximab in steroid-refractory Evans syndrome in a patient with ulcerative colitis

Hamid SHAABAN
Theodore DACOSTA JR
Sindhusha VEERABALLI
Eyad AHMED
Kok Hoe CHAN
Pages
156–157
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

SHAABAN, H., JR, T. D., VEERABALLI, S., AHMED, E., CHAN, K. H. (2022). Commensalism or symbiosis: The potential use of rituximab in steroid-refractory Evans syndrome in a patient with ulcerative colitis. Archives of Rheumatology, Cilt: 37 - Sayı: 1, 156–157. https://ajindex.com/articles/447976

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Norton A, Roberts I. Management of Evans syndrome. Br J Haematol 2006;132:125-37
  2. Shaikh H, Mewawalla P. Evans Syndrome. [Updated 2020 Jun 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available at:
  3. Jaime-Pérez JC, Aguilar-Calderón PE, SalazarCavazos L, Gómez-Almaguer D. Evans syndrome: Clinical perspectives, biological insights and treatment modalities. J Blood Med 2018;9:171-84
  4. Kashif M, Qureshi A, Adil SN, Khurshid M. Successful use of rituximab in Evans syndrome and refractory immune thrombocytopenic purpura. J Pak Med Assoc 2010;60:64-5
  5. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem 2006;52:171-81
  6. Lipka S, Katz S, Crawford JM. Fulminant colitis following rituximab therapy. Gastroenterol Hepatol (N Y) 2016;12:58-60
  7. Ardelean DS, Gonska T, Wires S, Cutz E, Griffiths A, Harvey E, et al. Severe ulcerative colitis after rituximab therapy. Pediatrics 2010;126:e243-6
  8. Leiper K, Martin K, Ellis A, Subramanian S, Watson AJ, Christmas SE, et al. Randomised placebocontrolled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 2011;60:1520-6.